Literature DB >> 20096762

Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation.

Marc Baguelin1, Albert Jan Van Hoek, Mark Jit, Stefan Flasche, Peter J White, W John Edmunds.   

Abstract

Decisions on how to mitigate an evolving pandemic are technically challenging. We present a real-time assessment of the effectiveness and cost-effectiveness of alternative influenza A/H1N1v vaccination strategies. A transmission dynamic model was fitted to the estimated number of cases in real-time, and used to generate plausible autumn scenarios under different vaccination options. The proportion of these cases by age and risk group leading to primary care consultations, National Pandemic Flu Service consultations, emergency attendances, hospitalisations, intensive care and death was then estimated using existing data from the pandemic. The real-time model suggests that the epidemic will peak in early November, with the peak height being similar in magnitude to the summer wave. Vaccination of the high-risk groups is estimated to prevent about 45 deaths (80% credibility interval 26-67), and save around 2900 QALYs (80% credibility interval 1600-4500). Such a programme is very likely to be cost-effective if the cost of vaccine purchase itself is treated as a sunk cost. Extending vaccination to low-risk individuals is expected to result in more modest gains in deaths and QALYs averted. Extending vaccination to school-age children would be the most cost-effective extension. The early availability of vaccines is crucial in determining the impact of such extensions. There have been a considerable number of cases of H1N1v in England, and so the benefits of vaccination to mitigate the ongoing autumn wave are limited. However, certain groups appear to be at significantly higher risk of complications and deaths, and so it appears both effective and cost-effective to vaccinate them. The United Kingdom was the first country to have a major epidemic in Europe. In countries where the epidemic is not so far advanced vaccination of children may be cost-effective. Similar, detailed, real-time modelling and economic studies could help to clarify the situation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096762     DOI: 10.1016/j.vaccine.2010.01.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  90 in total

Review 1.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

2.  Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1.

Authors:  Marc Lipsitch; Lyn Finelli; Richard T Heffernan; Gabriel M Leung; Stephen C Redd
Journal:  Biosecur Bioterror       Date:  2011-06

3.  Seven challenges for model-driven data collection in experimental and observational studies.

Authors:  J Lessler; W J Edmunds; M E Halloran; T D Hollingsworth; A L Lloyd
Journal:  Epidemics       Date:  2014-12-16       Impact factor: 4.396

4.  Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios.

Authors:  Paul E Parham; Dyfrig A Hughes
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-05       Impact factor: 6.237

Review 5.  The use of mathematical models to inform influenza pandemic preparedness and response.

Authors:  Joseph T Wu; Benjamin J Cowling
Journal:  Exp Biol Med (Maywood)       Date:  2011-07-04

Review 6.  Case fatality risk of influenza A (H1N1pdm09): a systematic review.

Authors:  Jessica Y Wong; Heath Kelly; Dennis K M Ip; Joseph T Wu; Gabriel M Leung; Benjamin J Cowling
Journal:  Epidemiology       Date:  2013-11       Impact factor: 4.822

7.  Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong.

Authors:  Jessica Y Wong; Peng Wu; Hiroshi Nishiura; Edward Goldstein; Eric H Y Lau; Lin Yang; S K Chuang; Thomas Tsang; J S Malik Peiris; Joseph T Wu; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2013-03-03       Impact factor: 4.897

8.  Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.

Authors:  Dan Yamin; Ran D Balicer; Alison P Galvani
Journal:  Vaccine       Date:  2014-06-12       Impact factor: 3.641

9.  Internet-based surveillance of Influenza-like-illness in the UK during the 2009 H1N1 influenza pandemic.

Authors:  Natasha L Tilston; Ken T D Eames; Daniela Paolotti; Toby Ealden; W John Edmunds
Journal:  BMC Public Health       Date:  2010-10-27       Impact factor: 3.295

10.  Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation.

Authors:  Marc Baguelin; Katja Hoschler; Elaine Stanford; Pauline Waight; Pia Hardelid; Nick Andrews; Elizabeth Miller
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.